for first and second ER-positive and ER-negative BCs ranged between 0.73 and 0.82.Conclusions:ThePREDICTtool largely underestimated the 5-year BC-specific mortality in women diagnosed with a second ER-positive breast cancer and in many subgroups of women diagnosed with a second ER-negative cancer...
PREDICT is a widely used online prognostication and treatment benefit tool for patients with early stage breast cancer. The aim of this study was to conduct an independent validation exercise of the most up-to-date version of the PREDICT algorithm (version 2) using real-world outcomes from the...
LONDON, March 15 (Xinhua) -- Scientists have been trying to better predict if and when women's breast cancer could come back using statistical tools. A team consisting of researchers from the University of Cambridge and Stanford University has examined the patterns of genetic changes within tumour...
Furthermore, the expected-observed difference is in keeping with a recent study, where the survival of BRCA1 carriers breast cancer was nominally higher than survival of non-carriers in pathology- and treatment-adjusted analysis of patients with ER-negative breast cancer18. BRCA2 variant carrier c...
A new online tool that could better predict the long-term risk of breast cancer returning in other areas of the body has been created. The prognostic tool, known as CTS5 (Clinical Treatment Score post-5-years), could be used to decide which patients are at high enough risk of their can...
Introduction PREDICT is a prognostication tool that calculates the potential benefit of various postsurgical treatments on the overall survival (OS) of patients with nonmetastatic invasive breast cancer. Once patient, tumor, and treatment details have been entered, the tool will show the estimated 5 ...
Our primary objective was to rely only on the BC H&E digital image and readily available clinical data to both standardize BC grading and provide an accessible tool to predict breast cancer recurrence within 6 years. Methods Study design We performed a retrospective longitudinal clinical development...
Breast cancer is the most common cancer in women worldwide1. It is a heterogeneous disease that causes difficulties for its diagnosis and treatment. Thus, multiple clinicopathological factors, such as the tumour size and lymph node metastasis, and established biomarkers, such as the estrogen receptor...
BC, breast cancer, CRC, colorectal cancer Full size image Currently, there is no standardised tool to enable the assessment of biomarkers and target research to those more likely to be clinically translated. There are enormous time and cost implications due to excessive research with very little ...
“It could be a game changer for breast cancer because now we can identify large numbers of women with different levels of risk, not just those at high risk.” The online tool comprises a set of questions regarding a patient, including medical and family history, genetic alterations related ...